Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer

被引：0
|
作者：
Spring, L. M. [1 ,2 ]
Han, H. [3 ]
Hamilton, E. [4 ]
Irie, H. [5 ]
Santa-Maria, C. A. [6 ]
Reeves, J. [7 ]
Pan, P. [8 ]
Shan, M. [8 ]
Tang, Y. [8 ]
Graham, J. R. [8 ]
Hazard, S. [8 ]
Ellisen, L. W. [1 ,2 ]
Isakoff, S. J. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Tampa, FL USA
[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Sarah Cannon Res Inst, Florida Canc Specialists South, Ft Myers, FL USA
[8] GSK, Waltham, MA USA
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P095
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [21] Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study
    Ales-Martinez, Jose E.
    Balmana, Judith
    Sanchez-Rovira, Pedro
    Bofill, Francisco Javier Salvador
    Garcia-Saenz, Jose Angel
    Pimentel, Isabel
    Murillo, Serafin Morales
    Fernandez, Adela
    Martinez, Ainhara Lahuerta
    Ferrer, Neus
    Zamora, Pilar
    Bermejo, Begona
    Diaz-Redondo, Tamara
    Lopez-Ceballos, Maria Helena
    Galan, Maria
    Malfettone, Andrea
    Calabuig, Laura
    Sampayo-Cordero, Miguel
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Veliparib, Carboplatin, and Paclitaxel in Patients with BRCA-mutated Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (01)
  • [23] Fertility and pregnancy issues in BRCA-mutated breast cancer patients
    Lambertini, Matteo
    Goldrat, Oranite
    Toss, Angela
    Azim, Hatem A., Jr.
    Peccatori, Fedro A.
    Ignatiadis, Michail
    Del Mastro, Lucia
    Demeestere, Isabelle
    CANCER TREATMENT REVIEWS, 2017, 59 : 61 - 70
  • [24] Talazoparib for BRCA-mutated advanced breast cancer
    Gunjur, Ashray
    LANCET ONCOLOGY, 2018, 19 (10): : E511 - E511
  • [25] Niraparib Efficacy and Safety in Patients With BRCA-Mutated Ovarian Cancer: Results From Three Phase 3 Niraparib Trials
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 7 - 8
  • [26] Lurbinectedin for BRCA-mutated advanced breast cancer
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (11): : E582 - E582
  • [27] Adjuvant Olaparib in BRCA-Mutated Breast Cancer
    Nozawa, Kazuki
    Yoshimura, Akiyo
    Iwata, Hiroji
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1439 - 1439
  • [28] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
    Balmana, J.
    Fasching, P. A.
    Delaloge, S.
    Park, Y. H.
    Eisen, A.
    Bourgeois, H.
    Kemp, Z.
    Jankowski, T.
    Sohn, J.
    Aksoy, S.
    Timcheva, C. V.
    Park-Simon, T-W.
    Torres, A. Anton
    John, E.
    Baria, K.
    Walker, G.
    Gelmon, K. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S205 - S206
  • [29] Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context
    Gonzalez-Martin, Antonio
    Matulonis, Ursula A.
    Korach, Jacob
    Mirza, Mansoor R.
    Moore, Kathleen N.
    Wu, Xiaohua
    York, Whitney
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    FUTURE ONCOLOGY, 2022, 18 (23) : 2505 - 2536
  • [30] Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer
    Garber, Haven
    Raghavendra, Akshara Singareeka
    Hess, Kenneth R.
    Arun, Banu
    Ibrahim, Nuhad K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345